Freedom Biosciences

🗓 Founded 2021👥 7 employees💰 Last funded Feb 2025
Biotechnology Research🌐 freedombio.co
Website LinkedIn
Freedom Biosciences is a clinical-stage biotechnology platform developing next-generation neuropsychiatric therapeutics. Through its discovery platform, Freedom Biosciences has identified the most efficacious combinations of chemicals to advance the safety and therapeutic profiles of existing therapeutics. With programs with clinical data and multiple exploratory programs, Freedom Biosciences has a diverse portfolio of assets that are positioned to significantly change the way we treat mental health indications. Freedom Biosciences is co-founded by Dr. John Krystal and Dina Burkitbayeva. Dr. John Krystal is the Chair of the Department of Psychiatry at Yale University and Chief of Psychiatry and Behavioral Health at Yale-New Haven Hospital. Dina Burkitbayeva is a co-founder of PsyMed Ventures.
3
Total investors
1
Early stage
2
Mid stage
0
Late stage
2021
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
2
United Kingdom
1
Investor activity2022–2025 · investors recorded per year
202212024120251
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Freedom Biosciences?
Freedom Biosciences has 3 investors on record on gritt.io, including 1 early-stage backers, 2 mid-stage.
When did Freedom Biosciences last raise funding?
The most recent investment in Freedom Biosciences recorded on gritt.io was in February 2025.
When was Freedom Biosciences founded?
Freedom Biosciences was founded in 2021.
What industry is Freedom Biosciences in?
Freedom Biosciences operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.